+Vote!
Fiercebiotech (Free subscription) | 09/25/2008
Wayne Pisano, who runs Sanofi-Aventis's vaccine arm, says that the newly acquired Acambis will be kept at arm's length with a minimum of bureaucratic controls to slow it down. But Pisano also conceded that fostering a small-company development mentality in a big pharma subsidiary would prove to be a challenge. But Sanofi definitely plans to grow Acambis. Pisano says he will finance new...
+Vote!
Red Orbit (Free subscription) | 09/26/2008
Sanofi Pasteur has announced that Sanofi Pasteur Holding has completed the acquisition of Acambis, a manufacturer of vaccines, for GBP285 million.
+Vote!
Financial Time (Free subscription) | 09/25/2008
, the French pharmaceutical group, is set to complete its acquisition of of the UK on Thursday, with plans to keep the vaccine developer partly autonomous, to maintain its entrepreneurial spirit.Wayne Pisano, head of Sanofi-Aventis’ vaccines arm, said the cash deal would reinforce the group’s presence in biological medicines, and accelerate Acambis’ pipeline of experimental products by providing...
+Vote!
The Telegraph (Free subscription) | 10/01/2008
... in a rapid clear-up of recurrent infections.Researchers at Cambridge-based biotech company Acambis hope the jab could have the same effect as the tetanus jab, first used almost a century ago, and which has proved almost 100 per cent effective. C diff produces a pair of poisons which irritate the lining of the bowel, causing diarrhoea and a potentially fatal infection of the abdomen.Treating...
+Vote!
Red Orbit (Free subscription) | 09/18/2008
... profiles 164 companies including many key and niche players worldwide such as ALK - Abello A/S, Acambis PLC, Bavarian Nordic A/S, Crucell N.V., CSL Ltd., GlaxoSmithKline PLC, GlaxoSmithKline Biologicals S.A, Medimmune, Inc, Merck & Company, Inc., Novartis Vaccines & Diagnostics, Inc., Sanofi-Aventis S A, Sanofi-Pasteur SA, Sanofi Pasteur, Inc., Shanta Biotechnics Ltd., Vaxin, Inc., and Wyeth....
+Vote!
Market Watch (Free subscription) | 09/25/2008
... at $33.82. Early Thursday, Sanofi said it had closed on its acquisition of U.K. vaccine developer Acambis PLC. Sanofi is a leading marketer of vaccines. Shares of Merck & Co. (:MRK, , , Last: Delayed quote dataSponsored by:, , ) were up 3% at $32.27. Merck said it had entered into a worldwide licensing agreement with Japan Tobacco Inc. (: , , ) for the development of that company's osteoporosis...
+Vote!
PR News Wire (Free subscription) | 09/22/2008
... disease.
Dr. Aphale was the former Vice President Operations and
Project/Portfolio Management at Acambis plc. At Acambis, Dr. Aphale was
responsible for R&D project management as well overseeing multiple vaccine
manufacturing plants, which included cGMP upstream and downstream
manufacturing, and a lyophilization facility. Dr. Aphale previously held
Director level positions at Wyeth...
+Vote!
Evening Standard (Free subscription) | 09/05/2008
... follows successful tests of another universal vaccine by scientists at Cambridge biotech firm Acambis. Trials on healthy adults in the U.S. showed the jab is safe, causing no side effects other than the occasional red arm and high temperature associated with all vaccines. The trials found that after two doses a month apart, it worked fast to prime the immune system to produce antibodies...
+Vote!
Daily Mail online | Home (Free subscription) | 09/05/2008
... of another universal vaccine announced earlier this year by scientists at Cambridge biotech firm Acambis.Trials on healthy young adults in the US showed the jab is safe, causing no side effects other than the occasional red arm and high temperature associated with all vaccines.The trials found after two doses a month apart it works fast to prime the immune system to produce antibodies capable...
+Vote!
Daily Mail on Sunday (Free subscription) | 09/05/2008
... of another universal vaccine announced earlier this year by scientists at Cambridge biotech firm Acambis.Trials on healthy young adults in the US showed the jab is safe, causing no side effects other than the occasional red arm and high temperature associated with all vaccines.The trials found after two doses a month apart it works fast to prime the immune system to produce antibodies capable...
+Vote!
The Independent (Free subscription) | 08/22/2008
... is that there are several examples in recent months of this happening: the British vaccine maker Acambis is being bought by Sanofi-Aventis of France, while the US group Genentech is being swallowed up by Roche, of Switzerland.There are those, however, who are worried about the future of the industry in the UK. Biotech has always struggled to raise funds from institutional investors, who...
